Topic: Bayer AG

Onyx, Bayer say Nexavar fails in lung cancer study

AP News - 602 days ago
Bayer and Onyx Pharmaceuticals say Nexavar does not meet study goal as a lung cancer treatmentBayer HealthCare and Onyx Pharmaceuticals Inc. said Monday their cancer treatment Nexavar failed to boost survival in a clinical study involving patients with a certain type of ...
Read More...

Phase III Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival

Drugs.com - 602 days ago
Berlin, June 14, 2010 - Bayer HealthCare and Onyx Pharmaceuticals today announced that the final analysis of the Phase III NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar? (sorafenib) tablets in patients with advanced non-squamous, non-small cell lung cancer (NSCLC) showed ...